David Fleischer
Concepts (464)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peanut Hypersensitivity | 57 | 2025 | 140 | 14.440 |
Why?
| Food Hypersensitivity | 51 | 2024 | 176 | 10.500 |
Why?
| Arachis | 44 | 2025 | 109 | 9.550 |
Why?
| Allergens | 56 | 2025 | 384 | 8.550 |
Why?
| Desensitization, Immunologic | 30 | 2025 | 90 | 6.210 |
Why?
| Infant Nutritional Physiological Phenomena | 11 | 2019 | 137 | 2.800 |
Why?
| Anaphylaxis | 13 | 2025 | 98 | 2.800 |
Why?
| Diet | 18 | 2024 | 1212 | 2.370 |
Why?
| Immunoglobulin E | 32 | 2024 | 329 | 2.170 |
Why?
| Dermatitis, Atopic | 13 | 2024 | 319 | 1.660 |
Why?
| Milk Hypersensitivity | 8 | 2024 | 19 | 1.630 |
Why?
| Transdermal Patch | 3 | 2020 | 15 | 1.490 |
Why?
| Eosinophilic Esophagitis | 10 | 2021 | 318 | 1.470 |
Why?
| Epinephrine | 5 | 2025 | 141 | 1.420 |
Why?
| Skin Tests | 19 | 2023 | 100 | 1.340 |
Why?
| Plant Proteins | 4 | 2025 | 89 | 1.210 |
Why?
| Immunotherapy | 9 | 2024 | 592 | 1.180 |
Why?
| Esophagoscopy | 12 | 2022 | 199 | 1.160 |
Why?
| Primary Prevention | 5 | 2022 | 188 | 1.150 |
Why?
| Hypersensitivity | 4 | 2025 | 248 | 1.090 |
Why?
| Infant | 45 | 2025 | 8975 | 1.060 |
Why?
| Egg Hypersensitivity | 11 | 2019 | 26 | 1.000 |
Why?
| Humans | 167 | 2025 | 129248 | 0.990 |
Why?
| Gastrointestinal Diseases | 9 | 2019 | 198 | 0.980 |
Why?
| Child | 60 | 2025 | 20773 | 0.970 |
Why?
| Infant Formula | 4 | 2023 | 74 | 0.960 |
Why?
| Administration, Cutaneous | 10 | 2025 | 124 | 0.920 |
Why?
| Child, Preschool | 37 | 2025 | 10456 | 0.900 |
Why?
| Nut Hypersensitivity | 3 | 2010 | 4 | 0.880 |
Why?
| Antigens, Plant | 6 | 2025 | 48 | 0.860 |
Why?
| Noncommunicable Diseases | 1 | 2023 | 15 | 0.850 |
Why?
| Breast Feeding | 8 | 2023 | 423 | 0.840 |
Why?
| Protein Hydrolysates | 3 | 2018 | 6 | 0.800 |
Why?
| Eczema | 10 | 2022 | 67 | 0.770 |
Why?
| Anti-Allergic Agents | 5 | 2024 | 45 | 0.770 |
Why?
| Hypersensitivity, Immediate | 3 | 2023 | 43 | 0.760 |
Why?
| Endoscopy, Gastrointestinal | 7 | 2022 | 219 | 0.740 |
Why?
| Immune Tolerance | 9 | 2023 | 355 | 0.710 |
Why?
| Female | 74 | 2025 | 68543 | 0.640 |
Why?
| Esophageal Stenosis | 5 | 2014 | 51 | 0.620 |
Why?
| Schools | 4 | 2021 | 439 | 0.610 |
Why?
| Double-Blind Method | 14 | 2025 | 1875 | 0.600 |
Why?
| Asthma | 8 | 2021 | 2220 | 0.560 |
Why?
| Esophageal Neoplasms | 9 | 2022 | 295 | 0.560 |
Why?
| Omalizumab | 3 | 2024 | 50 | 0.560 |
Why?
| Male | 62 | 2025 | 63501 | 0.540 |
Why?
| Gastroenterology | 2 | 2015 | 174 | 0.510 |
Why?
| Eosinophilia | 4 | 2013 | 204 | 0.500 |
Why?
| Practice Guidelines as Topic | 10 | 2024 | 1497 | 0.500 |
Why?
| Administration, Oral | 9 | 2022 | 785 | 0.490 |
Why?
| Pneumonia, Viral | 4 | 2020 | 339 | 0.480 |
Why?
| Coronavirus Infections | 4 | 2020 | 333 | 0.480 |
Why?
| Nasal Sprays | 2 | 2025 | 4 | 0.470 |
Why?
| Lye | 1 | 2014 | 1 | 0.460 |
Why?
| Caustics | 1 | 2014 | 7 | 0.460 |
Why?
| Dilatation | 2 | 2014 | 59 | 0.450 |
Why?
| Endosonography | 1 | 2015 | 143 | 0.450 |
Why?
| Burns, Chemical | 1 | 2014 | 29 | 0.440 |
Why?
| Adolescent | 25 | 2025 | 20303 | 0.440 |
Why?
| Feeding Behavior | 3 | 2019 | 622 | 0.430 |
Why?
| Barrett Esophagus | 3 | 2022 | 148 | 0.430 |
Why?
| Betacoronavirus | 3 | 2020 | 248 | 0.420 |
Why?
| Environmental Exposure | 1 | 2017 | 462 | 0.400 |
Why?
| Pandemics | 5 | 2020 | 1482 | 0.400 |
Why?
| Food | 5 | 2024 | 156 | 0.390 |
Why?
| Gastrointestinal Hemorrhage | 4 | 2007 | 121 | 0.380 |
Why?
| Cattle | 4 | 2024 | 977 | 0.360 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2020 | 1364 | 0.360 |
Why?
| Infant Food | 2 | 2023 | 65 | 0.360 |
Why?
| Allergy and Immunology | 3 | 2020 | 42 | 0.360 |
Why?
| Consensus | 7 | 2024 | 615 | 0.350 |
Why?
| United States | 24 | 2024 | 13828 | 0.350 |
Why?
| Esophagus | 8 | 2019 | 248 | 0.340 |
Why?
| Adenocarcinoma | 5 | 2022 | 898 | 0.340 |
Why?
| Milk Proteins | 3 | 2024 | 33 | 0.330 |
Why?
| Allergists | 3 | 2020 | 12 | 0.330 |
Why?
| Endoscopy | 7 | 2018 | 285 | 0.330 |
Why?
| Treatment Outcome | 12 | 2025 | 10199 | 0.330 |
Why?
| Virtual Reality | 2 | 2021 | 52 | 0.310 |
Why?
| Risk | 5 | 2018 | 854 | 0.310 |
Why?
| Young Adult | 13 | 2025 | 12388 | 0.300 |
Why?
| Capsule Endoscopy | 1 | 2007 | 18 | 0.280 |
Why?
| Adult | 25 | 2025 | 35495 | 0.280 |
Why?
| Intestinal Diseases | 1 | 2007 | 36 | 0.280 |
Why?
| Enterocolitis | 2 | 2020 | 17 | 0.270 |
Why?
| Severity of Illness Index | 6 | 2019 | 2737 | 0.270 |
Why?
| Colonoscopy | 4 | 2014 | 236 | 0.270 |
Why?
| Time Factors | 7 | 2020 | 6543 | 0.260 |
Why?
| Adrenal Cortex Hormones | 3 | 2017 | 522 | 0.260 |
Why?
| Brazil | 2 | 2023 | 154 | 0.260 |
Why?
| Capsules | 2 | 2005 | 40 | 0.250 |
Why?
| Rhinitis, Allergic | 3 | 2022 | 38 | 0.250 |
Why?
| National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 21 | 0.250 |
Why?
| Pregnancy | 9 | 2024 | 6391 | 0.240 |
Why?
| Administration, Sublingual | 3 | 2016 | 10 | 0.230 |
Why?
| Canada | 3 | 2020 | 350 | 0.230 |
Why?
| Immunomodulation | 2 | 2018 | 92 | 0.230 |
Why?
| Age Factors | 7 | 2018 | 3140 | 0.230 |
Why?
| Follow-Up Studies | 7 | 2020 | 4886 | 0.220 |
Why?
| Gastrointestinal Neoplasms | 3 | 2000 | 72 | 0.220 |
Why?
| Healthy Volunteers | 2 | 2024 | 200 | 0.210 |
Why?
| Diagnostic Imaging | 2 | 2006 | 327 | 0.210 |
Why?
| Constipation | 1 | 2024 | 88 | 0.210 |
Why?
| Intestinal Mucosa | 2 | 2015 | 589 | 0.200 |
Why?
| Eosinophils | 2 | 2018 | 324 | 0.200 |
Why?
| Laser Therapy | 5 | 1985 | 129 | 0.200 |
Why?
| Cross-Over Studies | 1 | 2024 | 521 | 0.190 |
Why?
| Middle Aged | 21 | 2025 | 31087 | 0.190 |
Why?
| Food Analysis | 1 | 2022 | 24 | 0.190 |
Why?
| Point-of-Care Testing | 1 | 2022 | 32 | 0.190 |
Why?
| Gastroesophageal Reflux | 2 | 2022 | 232 | 0.190 |
Why?
| Animals | 13 | 2024 | 35307 | 0.190 |
Why?
| Predictive Value of Tests | 3 | 2020 | 1946 | 0.190 |
Why?
| Child Day Care Centers | 1 | 2021 | 32 | 0.180 |
Why?
| Milk | 3 | 2018 | 119 | 0.180 |
Why?
| Aptamers, Nucleotide | 1 | 2022 | 77 | 0.180 |
Why?
| Dietary Exposure | 1 | 2020 | 5 | 0.180 |
Why?
| Restaurants | 1 | 2020 | 20 | 0.180 |
Why?
| Diet Therapy | 2 | 2017 | 34 | 0.170 |
Why?
| Infusions, Subcutaneous | 1 | 2020 | 21 | 0.170 |
Why?
| Eggs | 2 | 2018 | 25 | 0.170 |
Why?
| Deglutition Disorders | 2 | 2019 | 134 | 0.170 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2020 | 93 | 0.170 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2024 | 574 | 0.160 |
Why?
| Europe | 2 | 2022 | 363 | 0.160 |
Why?
| Respiratory Tract Infections | 1 | 2024 | 376 | 0.160 |
Why?
| Inservice Training | 1 | 2020 | 112 | 0.160 |
Why?
| Diagnosis, Differential | 3 | 2015 | 1430 | 0.160 |
Why?
| Immunization | 3 | 2017 | 411 | 0.160 |
Why?
| Quality of Life | 6 | 2022 | 2685 | 0.160 |
Why?
| Prevalence | 4 | 2024 | 2554 | 0.160 |
Why?
| United Kingdom | 4 | 2020 | 257 | 0.150 |
Why?
| Multiphasic Screening | 1 | 2018 | 1 | 0.150 |
Why?
| Meta-Analysis as Topic | 2 | 2016 | 170 | 0.150 |
Why?
| Confidence Intervals | 1 | 2019 | 316 | 0.150 |
Why?
| Population Groups | 1 | 2018 | 60 | 0.150 |
Why?
| Ambulatory Care Facilities | 1 | 2020 | 226 | 0.140 |
Why?
| Health Promotion | 1 | 2024 | 719 | 0.140 |
Why?
| Blood Pressure | 1 | 2025 | 1736 | 0.140 |
Why?
| Food, Genetically Modified | 1 | 2017 | 2 | 0.140 |
Why?
| Coal Tar | 1 | 2017 | 3 | 0.140 |
Why?
| Keratolytic Agents | 1 | 2017 | 5 | 0.140 |
Why?
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 4 | 0.140 |
Why?
| Skin Cream | 1 | 2017 | 12 | 0.140 |
Why?
| Plants, Genetically Modified | 1 | 2017 | 15 | 0.140 |
Why?
| Emollients | 1 | 2017 | 10 | 0.140 |
Why?
| Baths | 1 | 2017 | 15 | 0.140 |
Why?
| Histamine Antagonists | 1 | 2017 | 20 | 0.140 |
Why?
| Monitoring, Physiologic | 2 | 1990 | 265 | 0.140 |
Why?
| Clothing | 1 | 2017 | 19 | 0.140 |
Why?
| Crops, Agricultural | 1 | 2017 | 29 | 0.140 |
Why?
| Telemedicine | 3 | 2020 | 789 | 0.140 |
Why?
| School Health Services | 1 | 2020 | 233 | 0.140 |
Why?
| Calcineurin Inhibitors | 1 | 2017 | 68 | 0.140 |
Why?
| Risk Assessment | 4 | 2019 | 3233 | 0.130 |
Why?
| Mothers | 1 | 2023 | 730 | 0.130 |
Why?
| Prognosis | 2 | 2020 | 3772 | 0.130 |
Why?
| Palliative Care | 4 | 2010 | 706 | 0.130 |
Why?
| Nutritionists | 1 | 2016 | 16 | 0.130 |
Why?
| Education, Medical, Continuing | 1 | 2017 | 122 | 0.130 |
Why?
| Basophils | 2 | 2015 | 73 | 0.130 |
Why?
| Infant, Newborn | 6 | 2024 | 5736 | 0.130 |
Why?
| Surveys and Questionnaires | 7 | 2024 | 5382 | 0.130 |
Why?
| Kidney Transplantation | 1 | 2022 | 671 | 0.130 |
Why?
| Eating | 1 | 2019 | 368 | 0.130 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 104 | 0.130 |
Why?
| Bottle Feeding | 1 | 2016 | 21 | 0.130 |
Why?
| Decision Support Techniques | 1 | 2020 | 395 | 0.130 |
Why?
| Indonesia | 1 | 2015 | 21 | 0.120 |
Why?
| Health Care Reform | 2 | 1994 | 101 | 0.120 |
Why?
| Nutritional Requirements | 1 | 2016 | 77 | 0.120 |
Why?
| Membrane Proteins | 1 | 2022 | 1117 | 0.120 |
Why?
| Biological Products | 1 | 2018 | 200 | 0.120 |
Why?
| Aging | 1 | 2005 | 1774 | 0.120 |
Why?
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 33 | 0.120 |
Why?
| Catheter Ablation | 1 | 2019 | 335 | 0.120 |
Why?
| Sublingual Immunotherapy | 1 | 2015 | 5 | 0.120 |
Why?
| Probiotics | 1 | 2015 | 51 | 0.120 |
Why?
| Guideline Adherence | 1 | 2019 | 526 | 0.120 |
Why?
| Fluticasone | 1 | 2015 | 90 | 0.120 |
Why?
| History, 21st Century | 1 | 2015 | 183 | 0.120 |
Why?
| History, 20th Century | 1 | 2015 | 291 | 0.110 |
Why?
| Caregivers | 2 | 2020 | 808 | 0.110 |
Why?
| Anti-Bacterial Agents | 3 | 2017 | 1702 | 0.110 |
Why?
| Biopsy | 5 | 2019 | 1091 | 0.110 |
Why?
| Risk Factors | 7 | 2019 | 9745 | 0.110 |
Why?
| Wrist Injuries | 1 | 2014 | 28 | 0.110 |
Why?
| Premedication | 3 | 1990 | 42 | 0.110 |
Why?
| Physicians | 2 | 2020 | 859 | 0.110 |
Why?
| Cumulative Trauma Disorders | 1 | 2014 | 41 | 0.110 |
Why?
| Cost-Benefit Analysis | 1 | 2016 | 569 | 0.110 |
Why?
| Family | 2 | 2015 | 644 | 0.100 |
Why?
| Wrist Joint | 1 | 2014 | 64 | 0.100 |
Why?
| Occupational Injuries | 1 | 2014 | 45 | 0.100 |
Why?
| Information Systems | 1 | 1993 | 61 | 0.100 |
Why?
| Posture | 2 | 2014 | 175 | 0.100 |
Why?
| Epitopes | 2 | 2025 | 470 | 0.100 |
Why?
| Patient Education as Topic | 2 | 2015 | 737 | 0.100 |
Why?
| Societies, Medical | 2 | 1994 | 744 | 0.100 |
Why?
| Delivery of Health Care | 1 | 2020 | 892 | 0.100 |
Why?
| Evidence-Based Medicine | 1 | 2017 | 712 | 0.100 |
Why?
| Sympathomimetics | 1 | 2012 | 23 | 0.100 |
Why?
| Mucositis | 1 | 2012 | 19 | 0.100 |
Why?
| Recurrence | 3 | 2004 | 1005 | 0.100 |
Why?
| Poisson Distribution | 1 | 2012 | 73 | 0.100 |
Why?
| Pregnenediones | 1 | 2012 | 20 | 0.100 |
Why?
| Prospective Studies | 7 | 2019 | 7121 | 0.100 |
Why?
| Oximetry | 2 | 1990 | 87 | 0.100 |
Why?
| Patient Compliance | 2 | 2016 | 563 | 0.100 |
Why?
| Disease Management | 3 | 2024 | 588 | 0.090 |
Why?
| Cohort Studies | 5 | 2022 | 5408 | 0.090 |
Why?
| Health Surveys | 2 | 2012 | 493 | 0.090 |
Why?
| Child Development | 1 | 2016 | 457 | 0.090 |
Why?
| Bacterial Proteins | 1 | 2017 | 833 | 0.090 |
Why?
| Self Care | 1 | 2014 | 365 | 0.090 |
Why?
| Stents | 3 | 2000 | 502 | 0.090 |
Why?
| Patient Satisfaction | 1 | 2015 | 632 | 0.090 |
Why?
| Curriculum | 1 | 2017 | 910 | 0.090 |
Why?
| Biomarkers | 2 | 2020 | 3966 | 0.090 |
Why?
| Symptom Assessment | 1 | 2012 | 125 | 0.090 |
Why?
| Feeding and Eating Disorders of Childhood | 1 | 2010 | 7 | 0.090 |
Why?
| Metaplasia | 2 | 2022 | 54 | 0.090 |
Why?
| Practice Patterns, Physicians' | 1 | 2019 | 1267 | 0.090 |
Why?
| Health Policy | 1 | 1993 | 351 | 0.080 |
Why?
| Immunoassay | 1 | 2010 | 107 | 0.080 |
Why?
| Adaptation, Psychological | 1 | 2015 | 614 | 0.080 |
Why?
| Flavoring Agents | 1 | 1990 | 8 | 0.080 |
Why?
| Cathartics | 1 | 1990 | 15 | 0.080 |
Why?
| Citrates | 1 | 1990 | 42 | 0.080 |
Why?
| Phenotype | 1 | 2018 | 3074 | 0.080 |
Why?
| Disease Progression | 4 | 2019 | 2630 | 0.080 |
Why?
| Immunologic Factors | 2 | 2022 | 230 | 0.080 |
Why?
| Coloring Agents | 1 | 1990 | 77 | 0.080 |
Why?
| Regression Analysis | 1 | 2012 | 991 | 0.080 |
Why?
| Duodenoscopy | 1 | 1989 | 7 | 0.080 |
Why?
| Diet Surveys | 2 | 2024 | 92 | 0.080 |
Why?
| Gastroscopy | 1 | 1989 | 18 | 0.080 |
Why?
| Epithelial Cells | 2 | 2014 | 1063 | 0.080 |
Why?
| Retrospective Studies | 6 | 2024 | 14455 | 0.080 |
Why?
| Food, Formulated | 1 | 2009 | 14 | 0.080 |
Why?
| Drainage | 1 | 2010 | 164 | 0.080 |
Why?
| Inflammatory Bowel Diseases | 1 | 2013 | 320 | 0.080 |
Why?
| Maternal Exposure | 1 | 2010 | 177 | 0.080 |
Why?
| Lasers | 3 | 1985 | 132 | 0.080 |
Why?
| Physician-Patient Relations | 1 | 1993 | 538 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2013 | 1202 | 0.070 |
Why?
| Light Coagulation | 1 | 1988 | 9 | 0.070 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 758 | 0.070 |
Why?
| Physical Examination | 1 | 2009 | 234 | 0.070 |
Why?
| Precancerous Conditions | 2 | 2019 | 163 | 0.070 |
Why?
| Hypnotics and Sedatives | 1 | 1989 | 175 | 0.070 |
Why?
| Cholestasis | 1 | 2010 | 232 | 0.070 |
Why?
| Digestive System | 2 | 2002 | 29 | 0.070 |
Why?
| Feces | 1 | 1990 | 441 | 0.070 |
Why?
| Antibodies, Monoclonal | 1 | 2013 | 1367 | 0.070 |
Why?
| Risk Reduction Behavior | 2 | 2019 | 209 | 0.060 |
Why?
| Sepsis | 2 | 1989 | 572 | 0.060 |
Why?
| Immunologic Tests | 1 | 2005 | 16 | 0.060 |
Why?
| Remission, Spontaneous | 1 | 2005 | 37 | 0.060 |
Why?
| Reproducibility of Results | 2 | 2024 | 3079 | 0.060 |
Why?
| Equipment Safety | 1 | 2005 | 37 | 0.060 |
Why?
| Equipment Design | 2 | 2005 | 513 | 0.060 |
Why?
| Aged | 14 | 2019 | 22032 | 0.060 |
Why?
| Anti-Inflammatory Agents | 1 | 2009 | 480 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2022 | 1837 | 0.060 |
Why?
| Dietetics | 2 | 2017 | 22 | 0.060 |
Why?
| Esophageal and Gastric Varices | 1 | 1985 | 37 | 0.060 |
Why?
| Administration, Intranasal | 1 | 2024 | 84 | 0.060 |
Why?
| Immunoglobulin G | 3 | 2014 | 848 | 0.060 |
Why?
| Procainamide | 1 | 1984 | 6 | 0.060 |
Why?
| Hyperplasia | 2 | 2022 | 171 | 0.060 |
Why?
| Injections, Intramuscular | 1 | 2024 | 115 | 0.060 |
Why?
| Nutrition Assessment | 1 | 2024 | 85 | 0.060 |
Why?
| Therapeutic Irrigation | 1 | 1984 | 75 | 0.050 |
Why?
| Pollen | 1 | 2023 | 23 | 0.050 |
Why?
| Intestinal Absorption | 1 | 1984 | 99 | 0.050 |
Why?
| Excipients | 1 | 2023 | 52 | 0.050 |
Why?
| Delphi Technique | 1 | 2024 | 225 | 0.050 |
Why?
| Turkey | 1 | 2022 | 19 | 0.050 |
Why?
| Digestive System Diseases | 1 | 2002 | 25 | 0.050 |
Why?
| Software | 1 | 2007 | 606 | 0.050 |
Why?
| Maternal Nutritional Physiological Phenomena | 1 | 2024 | 169 | 0.050 |
Why?
| Vitamins | 1 | 2024 | 173 | 0.050 |
Why?
| Metals | 2 | 2000 | 123 | 0.050 |
Why?
| Immunity | 1 | 2023 | 138 | 0.050 |
Why?
| Hemoglobinuria, Paroxysmal | 1 | 2002 | 6 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2011 | 4057 | 0.050 |
Why?
| HLA Antigens | 1 | 2022 | 234 | 0.050 |
Why?
| Adrenergic alpha-Agonists | 1 | 2020 | 28 | 0.040 |
Why?
| Injections | 1 | 2021 | 174 | 0.040 |
Why?
| Japan | 1 | 2000 | 98 | 0.040 |
Why?
| Educational Personnel | 1 | 2020 | 12 | 0.040 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 206 | 0.040 |
Why?
| Terbutaline | 1 | 2020 | 8 | 0.040 |
Why?
| Respiratory Sounds | 1 | 2021 | 118 | 0.040 |
Why?
| Liver Cirrhosis, Biliary | 1 | 2000 | 18 | 0.040 |
Why?
| Cholestasis, Intrahepatic | 1 | 2000 | 39 | 0.040 |
Why?
| China | 1 | 2000 | 192 | 0.040 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2020 | 64 | 0.040 |
Why?
| Albuterol | 1 | 2020 | 102 | 0.040 |
Why?
| Interprofessional Relations | 2 | 1994 | 275 | 0.040 |
Why?
| Food Contamination | 1 | 2019 | 44 | 0.040 |
Why?
| Bronchodilator Agents | 1 | 2021 | 241 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2018 | 82 | 0.040 |
Why?
| Medical History Taking | 1 | 2019 | 119 | 0.040 |
Why?
| Esophagogastric Junction | 1 | 2019 | 50 | 0.040 |
Why?
| Leukocytes, Mononuclear | 2 | 2012 | 545 | 0.040 |
Why?
| Intestines | 1 | 2002 | 347 | 0.040 |
Why?
| Ischemia | 1 | 2002 | 406 | 0.040 |
Why?
| Health Planning Guidelines | 1 | 2018 | 25 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2019 | 2276 | 0.040 |
Why?
| New Zealand | 1 | 2018 | 45 | 0.040 |
Why?
| Efferent Pathways | 1 | 1998 | 17 | 0.040 |
Why?
| Drug Delivery Systems | 1 | 2021 | 333 | 0.040 |
Why?
| Psychometrics | 1 | 2022 | 691 | 0.040 |
Why?
| Food Labeling | 1 | 2017 | 14 | 0.040 |
Why?
| Hydrolysis | 1 | 2018 | 186 | 0.040 |
Why?
| Locus Coeruleus | 1 | 1998 | 21 | 0.040 |
Why?
| Markov Chains | 1 | 2018 | 117 | 0.040 |
Why?
| Cross Reactions | 1 | 2017 | 132 | 0.040 |
Why?
| Early Medical Intervention | 1 | 2018 | 57 | 0.040 |
Why?
| Immune Sera | 1 | 2017 | 87 | 0.040 |
Why?
| Endoscopy, Digestive System | 1 | 2019 | 122 | 0.040 |
Why?
| RNA, Viral | 1 | 2021 | 619 | 0.040 |
Why?
| Skin Irritancy Tests | 1 | 2017 | 2 | 0.030 |
Why?
| Australia | 1 | 2018 | 243 | 0.030 |
Why?
| Metiamide | 1 | 1977 | 1 | 0.030 |
Why?
| Thiourea | 1 | 1977 | 39 | 0.030 |
Why?
| Agranulocytosis | 1 | 1977 | 30 | 0.030 |
Why?
| Guanidines | 1 | 1977 | 36 | 0.030 |
Why?
| Health Care Surveys | 1 | 2019 | 557 | 0.030 |
Why?
| Societies, Scientific | 1 | 2017 | 45 | 0.030 |
Why?
| Norepinephrine | 1 | 1998 | 210 | 0.030 |
Why?
| Antibody Specificity | 1 | 2017 | 184 | 0.030 |
Why?
| Uncertainty | 1 | 2017 | 116 | 0.030 |
Why?
| Consensus Development Conferences as Topic | 1 | 2016 | 27 | 0.030 |
Why?
| Nutritional Sciences | 1 | 2017 | 42 | 0.030 |
Why?
| Protective Factors | 1 | 2017 | 91 | 0.030 |
Why?
| Transgenes | 1 | 2017 | 177 | 0.030 |
Why?
| Carcinoma, Squamous Cell | 2 | 2000 | 625 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2017 | 184 | 0.030 |
Why?
| Incidence | 2 | 2019 | 2636 | 0.030 |
Why?
| Probability | 1 | 2017 | 305 | 0.030 |
Why?
| Drug Dosage Calculations | 1 | 2016 | 22 | 0.030 |
Why?
| Imidazoles | 1 | 1977 | 234 | 0.030 |
Why?
| Injections, Subcutaneous | 1 | 2016 | 147 | 0.030 |
Why?
| Protein Binding | 1 | 2022 | 2120 | 0.030 |
Why?
| Mass Screening | 2 | 2019 | 1149 | 0.030 |
Why?
| Mouth | 1 | 2015 | 84 | 0.030 |
Why?
| Mice | 1 | 2011 | 16915 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2022 | 1933 | 0.030 |
Why?
| Endoscopes | 2 | 1985 | 17 | 0.030 |
Why?
| Calpain | 1 | 2014 | 57 | 0.030 |
Why?
| Longitudinal Studies | 2 | 2012 | 2716 | 0.030 |
Why?
| Synapses | 1 | 1998 | 396 | 0.030 |
Why?
| Population Surveillance | 1 | 2017 | 438 | 0.030 |
Why?
| Steroids | 1 | 2014 | 158 | 0.030 |
Why?
| Organ Specificity | 1 | 2014 | 295 | 0.030 |
Why?
| Interleukin-13 | 1 | 2014 | 147 | 0.030 |
Why?
| Aged, 80 and over | 5 | 2010 | 7055 | 0.030 |
Why?
| Public Opinion | 1 | 1993 | 64 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2019 | 958 | 0.030 |
Why?
| Eosinophil Granule Proteins | 1 | 2012 | 21 | 0.030 |
Why?
| Lysophospholipase | 1 | 2012 | 10 | 0.020 |
Why?
| Haplotypes | 1 | 2014 | 475 | 0.020 |
Why?
| Liver Transplantation | 1 | 2000 | 831 | 0.020 |
Why?
| Carboxylic Ester Hydrolases | 1 | 2012 | 20 | 0.020 |
Why?
| Biomedical Research | 1 | 2018 | 637 | 0.020 |
Why?
| Forecasting | 1 | 1994 | 359 | 0.020 |
Why?
| Survival Rate | 2 | 2010 | 1869 | 0.020 |
Why?
| Patient Acceptance of Health Care | 1 | 2018 | 757 | 0.020 |
Why?
| Movement | 1 | 2014 | 269 | 0.020 |
Why?
| Mucous Membrane | 1 | 2012 | 122 | 0.020 |
Why?
| Range of Motion, Articular | 1 | 2014 | 366 | 0.020 |
Why?
| Models, Genetic | 1 | 2014 | 593 | 0.020 |
Why?
| Specimen Handling | 1 | 2012 | 162 | 0.020 |
Why?
| Up-Regulation | 1 | 2014 | 839 | 0.020 |
Why?
| Postoperative Complications | 1 | 2022 | 2473 | 0.020 |
Why?
| Abdominal Pain | 2 | 2002 | 143 | 0.020 |
Why?
| Mutation | 1 | 2022 | 3710 | 0.020 |
Why?
| Biomechanical Phenomena | 1 | 2014 | 757 | 0.020 |
Why?
| Age of Onset | 1 | 2012 | 496 | 0.020 |
Why?
| Professional Role | 1 | 2012 | 157 | 0.020 |
Why?
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 7 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2012 | 645 | 0.020 |
Why?
| Glycoproteins | 1 | 2012 | 338 | 0.020 |
Why?
| Gallbladder Neoplasms | 1 | 2010 | 20 | 0.020 |
Why?
| Comorbidity | 1 | 2015 | 1544 | 0.020 |
Why?
| Midazolam | 1 | 1990 | 53 | 0.020 |
Why?
| Citric Acid | 1 | 1990 | 30 | 0.020 |
Why?
| Anesthesiology | 1 | 1990 | 45 | 0.020 |
Why?
| Computer Simulation | 1 | 2014 | 939 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2020 | 5045 | 0.020 |
Why?
| Endocarditis, Bacterial | 1 | 1989 | 42 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 212 | 0.020 |
Why?
| Health Status | 1 | 2014 | 754 | 0.020 |
Why?
| Cholangiocarcinoma | 1 | 2010 | 77 | 0.020 |
Why?
| Genetic Variation | 1 | 2014 | 938 | 0.020 |
Why?
| Genotype | 1 | 2014 | 1835 | 0.020 |
Why?
| Pancreatic Neoplasms | 2 | 2010 | 881 | 0.020 |
Why?
| Neurons | 1 | 1998 | 1494 | 0.020 |
Why?
| Bile Duct Neoplasms | 1 | 2010 | 99 | 0.020 |
Why?
| Pneumoperitoneum | 1 | 1988 | 12 | 0.020 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 18 | 0.020 |
Why?
| Anxiety | 1 | 2015 | 962 | 0.020 |
Why?
| Social Support | 1 | 2012 | 582 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2014 | 1327 | 0.020 |
Why?
| Electrocoagulation | 1 | 1987 | 37 | 0.020 |
Why?
| Cell Movement | 1 | 2012 | 944 | 0.020 |
Why?
| Pediatrics | 1 | 2015 | 1047 | 0.020 |
Why?
| Gastrostomy | 1 | 1988 | 110 | 0.020 |
Why?
| Electrocardiography | 1 | 1990 | 608 | 0.020 |
Why?
| Stress, Psychological | 1 | 2015 | 1065 | 0.020 |
Why?
| Parents | 1 | 2015 | 1308 | 0.020 |
Why?
| Duodenal Ulcer | 1 | 1985 | 11 | 0.020 |
Why?
| Drug Design | 1 | 2006 | 156 | 0.020 |
Why?
| Genetic Markers | 1 | 2006 | 336 | 0.020 |
Why?
| Hemostatic Techniques | 1 | 1985 | 45 | 0.010 |
Why?
| Arteriovenous Malformations | 1 | 1985 | 27 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1985 | 173 | 0.010 |
Why?
| Health Services Accessibility | 1 | 2012 | 899 | 0.010 |
Why?
| Stomach Neoplasms | 1 | 1985 | 99 | 0.010 |
Why?
| Random Allocation | 1 | 1985 | 346 | 0.010 |
Why?
| Electrolytes | 1 | 1984 | 59 | 0.010 |
Why?
| Quinidine | 1 | 1983 | 6 | 0.010 |
Why?
| Streptococcal Infections | 1 | 1985 | 148 | 0.010 |
Why?
| Tablets | 1 | 1983 | 35 | 0.010 |
Why?
| Cholelithiasis | 1 | 2002 | 36 | 0.010 |
Why?
| Biliary Tract Neoplasms | 1 | 2002 | 25 | 0.010 |
Why?
| Gallstones | 1 | 2002 | 31 | 0.010 |
Why?
| Colorectal Neoplasms | 1 | 2010 | 752 | 0.010 |
Why?
| Colonic Diseases | 1 | 1982 | 32 | 0.010 |
Why?
| Iran | 1 | 2002 | 38 | 0.010 |
Why?
| Jejunum | 1 | 2002 | 30 | 0.010 |
Why?
| Pancreatitis | 1 | 2002 | 129 | 0.010 |
Why?
| Duodenum | 1 | 2002 | 75 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| Microscopy, Electron | 1 | 2002 | 426 | 0.010 |
Why?
| Dogs | 1 | 1982 | 382 | 0.010 |
Why?
| Rectal Neoplasms | 1 | 1982 | 136 | 0.010 |
Why?
| Age Distribution | 1 | 2002 | 372 | 0.010 |
Why?
| Sex Distribution | 1 | 2002 | 359 | 0.010 |
Why?
| Granulation Tissue | 1 | 2000 | 6 | 0.010 |
Why?
| Foreign-Body Reaction | 1 | 2000 | 27 | 0.010 |
Why?
| Pruritus | 1 | 2000 | 58 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 978 | 0.010 |
Why?
| Equipment Failure Analysis | 1 | 2000 | 131 | 0.010 |
Why?
| Aspirin | 1 | 1983 | 380 | 0.010 |
Why?
| Axonal Transport | 1 | 1998 | 26 | 0.010 |
Why?
| Neuropeptides | 1 | 1998 | 71 | 0.010 |
Why?
| Fibrosis | 1 | 2000 | 520 | 0.010 |
Why?
| Neurons, Afferent | 1 | 1998 | 99 | 0.010 |
Why?
| Tracheoesophageal Fistula | 1 | 1997 | 33 | 0.010 |
Why?
| Biocompatible Materials | 1 | 2000 | 388 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2000 | 1290 | 0.010 |
Why?
| Brain Mapping | 1 | 1998 | 574 | 0.010 |
Why?
| False Positive Reactions | 1 | 1988 | 114 | 0.000 |
Why?
| Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| Radiography | 1 | 1988 | 794 | 0.000 |
Why?
| Drinking | 1 | 1983 | 39 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1987 | 1004 | 0.000 |
Why?
| Deglutition | 1 | 1983 | 67 | 0.000 |
Why?
| Esophagitis | 1 | 1983 | 68 | 0.000 |
Why?
| Pilot Projects | 1 | 1987 | 1584 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|